Research progress of insulin resistance markers in atherogenesis

doi:10.16352/j.issn.1001-6325.2022.08.1302

Abstract

Abstract: Insulin resistance (IR) is the pivotal link between metabolic disorders and atherosclerosis (AS). Insulin resistance plays an important role in the initiation and progression of atherosclerosis, and its underlying mechanism involves complex pathophysiological processes including endothelial injury, inflammatory reaction, and oxidative stress. Insulin resistance markers presented the potential association of metabolic risk with atherosclerosis and the detection of insulin resistance markers may support strategy development for the clinical management of cardiovascular diseases.

Key words: insulin resistance, surrogate markers, atherosclerosis

CLC Number:

R541.4

ZHAO Mao-yu, LI You-mei, LIU Huan-yun, MAO Qi. Research progress of insulin resistance markers in atherogenesis[J]. Basic & Clinical Medicine, 2022, 42(8): 1302-1305.

References 24

[1]	Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development[J]. Nat Rev Endocrinol, 2014, 10:293-302.
[2]	Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease[J]. Cardiovasc Diabetol, 2018, 17:122.doi:10.1186/s12933-018-0762-4.
[3]	Di Pino A, Defronzo RA. Insulin resistance and atherosclerosis:implications for insulin-sensitizing agents[J]. Endocr Rev, 2019, 40:1447-1467.
[4]	Saklayen MG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep, 2018, 20:12.doi:10.1007/s11906-018-0812-z.
[5]	Koren D, Taveras EM. Association of sleep disturbances with obesity, insulin resistance and the metabolic syn-drome[J]. Metabolism, 2018, 84:67-75.
[6]	Bornfeldt KE, Tabas L. Insulin resistance, hyperglycemia, and atherosclerosis[J]. Cell Metab, 2011, 14:575-585.
[7]	Biobaku F, Ghanim H, Batra M, et al. Macronutrient-mediated inflammation and oxidative stress:relevance to insulin resistance, obesity, and atherogenesis[J]. J Clin Endocrinol Metab, 2019, 104:6118-6128.
[8]	Schulman IG. Liver X receptors link lipid metabolism and inflammation[J]. FEBS lett, 2017, 591:2978-2991.
[9]	Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome[J]. Semin Immunopathol, 2018, 40:215-224.
[10]	Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease[J]. Cardiovasc Diabetol, 2018, 17:122.doi:10.1186/s12933-018-0762-4.
[11]	Onyango AN, Claudio C, Cabello-Verrugio C. Cellular stresses and stress responses in the pathogenesis of insulin resistance[J]. Oxid Med Cell Longev, 2018, 2018:4321714-4321727.
[12]	Zhao L, Varghese Z, Moorhead JF, et al. CD36 and lipid metabolism in the evolution of atherosclerosis[J]. Brit Med Bull, 2018, 126:101-112.
[13]	Glatz J, Luiken J. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization[J]. J Lipid Res, 2018, 59:1084-1093.
[14]	Son N, Basu D, Samovski D, et al. Endothelial cell CD36 optimizes tissue fatty acid uptake[J]. J Clin Invest, 2018, 128:4329-4342.
[15]	Deng Y, Li G, Chang D, et al. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases[J]. Clin Chim Acta, 2020, 511:40-46.
[16]	Akboga MK. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome[J]. Anato J Cardiol, 2016, 16:953-958.
[17]	Park HK, Kwak MK, Kim HJ, et al. Linking resistin, inflammation, and cardiometabolic diseases[J]. Korean J Intern Med, 2017, 32:239-247.
[18]	Helfer G, Wu Q. Chemerin:a multifaceted adipokine involved in metabolic disorders[J]. J Endocrinol, 2018, 238:R79-R94.
[19]	Zhang Z, Wang J, Wang H. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus[J]. Exp Ther Med, 2018, 15:2936-2940.
[20]	Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance:past, present and future[J]. Crit Rev Clin Lab Sci, 2015, 52:180-190.
[21]	Ahmad R, Thomas R, Kochumon S, et al. Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity[J]. Immun Inflamm Dis, 2017, 5:318-335.
[22]	Gong Z, Zhang X, Su K, et al. Deficiency in AIM2 induces inflammation and adipogenesis in white adipose tissue leading to obesity and insulin resistance[J]. Diabetologia, 2019, 62:2325-2339.
[23]	Akbarzadeh M, Eftekhari MH, Dabbaghmanesh MH, et al. Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes[J]. Iran J Immunol, 2013, 10:167-176.
[24]	Bankul A, Mitra P, Suri S, et al. Increased serum IL-18 levels and IL-18R expression in newly diagnosed type 2 diabetes mellitus[J]. Minerva Endocrinol, 2020.doi:10.23736/s0391-1977.20.03271-x.